SUPN

SUPN

USD

Supernus Pharmaceuticals Inc. Common Stock

$57.000+1.570 (2.832%)

实时价格

Healthcare
Drug Manufacturers - Specialty & Generic
美国

价格图表

Loading Chart...

关键指标

市场指标
公司基本面
交易统计

市场指标

开盘价

$55.430

最高价

$57.400

最低价

$54.610

成交量

4.00M

公司基本面

市值

3.2B

所属行业

Drug Manufacturers - Specialty & Generic

国家/地区

United States

交易统计

平均成交量

0.82M

交易所

NGM

货币

USD

52周价格范围

最低价 $29.16当前价 $57.000最高价 $57.65

相关新闻

Analyst Upgrades

B of A Securities Initiates Coverage On Supernus Pharmaceuticals with Buy Rating, Announces Price Target of $65

B of A Securities analyst Pavan Patel initiates coverage on Supernus Pharmaceuticals with a Buy rating and announces Price Target of $65.

查看更多
B of A Securities Initiates Coverage On Supernus Pharmaceuticals with Buy Rating, Announces Price Target of $65
Analyst Upgrades

TD Cowen Maintains Buy on Supernus Pharmaceuticals, Raises Price Target to $60

TD Cowen analyst Stacy Ku maintains Supernus Pharmaceuticals with a Buy and raises the price target from $45 to $60.

查看更多
TD Cowen Maintains Buy on Supernus Pharmaceuticals, Raises Price Target to $60
GlobeNewswire

Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025

ROCKVILLE, Md., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system

查看更多
Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
Analyst Upgrades

Piper Sandler Upgrades Supernus Pharmaceuticals to Overweight, Raises Price Target to $65

Piper Sandler analyst David Amsellem upgrades Supernus Pharmaceuticals from Neutral to Overweight and raises the price target from $40 to $65.

查看更多
Piper Sandler Upgrades Supernus Pharmaceuticals to Overweight, Raises Price Target to $65